Avedro Announces FDA Priority Review Status for Corneal Cross-linking New Drug Application

Avedro Announces FDA Priority Review Status! – Corneal Cross-linking!

This is huge news for the keratoconic community. The priority review status for the New Drug Application (NDA) places the application action date at March 15th, 2014.

request a free consultation
request appointment
contact us